{"status": "Succeeded", "recognitionResults": [{"page": 1, "clockwiseOrientation": 0.05, "width": 1706, "height": 2285, "unit": "pixel", "lines": [{"boundingBox": [205, 203, 308, 199, 309, 231, 207, 236], "text": "ACOG", "words": [{"boundingBox": [210, 204, 301, 200, 301, 232, 209, 234], "text": "ACOG"}]}, {"boundingBox": [800, 202, 863, 204, 861, 236, 797, 234], "text": "May", "words": [{"boundingBox": [800, 201, 861, 203, 860, 235, 799, 233], "text": "May"}]}, {"boundingBox": [1106, 200, 1176, 202, 1177, 231, 1106, 229], "text": "USA", "words": [{"boundingBox": [1111, 200, 1175, 201, 1174, 230, 1110, 229], "text": "USA"}]}, {"boundingBox": [205, 241, 304, 240, 305, 270, 205, 271], "text": "EMAS", "words": [{"boundingBox": [207, 241, 301, 241, 303, 271, 208, 271], "text": "EMAS"}]}, {"boundingBox": [807, 242, 880, 242, 877, 274, 807, 272], "text": "May", "words": [{"boundingBox": [809, 240, 877, 241, 876, 273, 808, 272], "text": "May"}]}, {"boundingBox": [1085, 239, 1221, 240, 1220, 271, 1084, 270], "text": "Romania", "words": [{"boundingBox": [1086, 240, 1220, 240, 1221, 270, 1085, 269], "text": "Romania"}]}, {"boundingBox": [202, 275, 302, 276, 301, 307, 201, 306], "text": "NAMS", "words": [{"boundingBox": [206, 276, 303, 276, 302, 308, 206, 306], "text": "NAMS"}]}, {"boundingBox": [808, 279, 865, 281, 864, 309, 807, 307], "text": "Sep", "words": [{"boundingBox": [810, 279, 864, 280, 863, 308, 809, 307], "text": "Sep"}]}, {"boundingBox": [1106, 275, 1176, 278, 1175, 308, 1105, 306], "text": "USA", "words": [{"boundingBox": [1108, 274, 1174, 276, 1173, 307, 1106, 305], "text": "USA"}]}, {"boundingBox": [205, 315, 307, 317, 306, 349, 205, 350], "text": "ASRM", "words": [{"boundingBox": [209, 314, 298, 314, 298, 349, 209, 349], "text": "ASRM"}]}, {"boundingBox": [809, 317, 864, 318, 864, 348, 809, 347], "text": "Oct", "words": [{"boundingBox": [808, 316, 862, 317, 862, 347, 808, 346], "text": "Oct"}]}, {"boundingBox": [1107, 316, 1180, 316, 1180, 347, 1108, 347], "text": "USA", "words": [{"boundingBox": [1109, 316, 1177, 316, 1177, 347, 1109, 347], "text": "USA"}]}, {"boundingBox": [204, 476, 640, 478, 639, 517, 203, 515], "text": "9 MARKET SUPPORT", "words": [{"boundingBox": [209, 476, 235, 477, 236, 516, 211, 516], "text": "9"}, {"boundingBox": [266, 477, 438, 478, 439, 517, 267, 516], "text": "MARKET"}, {"boundingBox": [446, 479, 640, 479, 639, 518, 446, 517], "text": "SUPPORT"}]}, {"boundingBox": [207, 560, 1436, 561, 1435, 597, 206, 596], "text": "The availability of Premarin 0.625/TMG will allow W-A to introduce a new progestin", "words": [{"boundingBox": [210, 561, 267, 561, 267, 597, 211, 597], "text": "The"}, {"boundingBox": [274, 561, 430, 561, 431, 598, 274, 597], "text": "availability"}, {"boundingBox": [437, 561, 465, 561, 466, 598, 438, 598], "text": "of"}, {"boundingBox": [472, 561, 612, 561, 613, 598, 473, 598], "text": "Premarin"}, {"boundingBox": [619, 561, 784, 562, 786, 598, 620, 598], "text": "0.625/TMG"}, {"boundingBox": [794, 562, 843, 562, 845, 598, 795, 598], "text": "will"}, {"boundingBox": [850, 562, 926, 562, 928, 598, 852, 598], "text": "allow"}, {"boundingBox": [935, 562, 1002, 562, 1003, 597, 937, 598], "text": "W-A"}, {"boundingBox": [1009, 562, 1039, 562, 1041, 597, 1011, 597], "text": "to"}, {"boundingBox": [1047, 562, 1188, 563, 1190, 597, 1048, 597], "text": "introduce"}, {"boundingBox": [1195, 563, 1214, 563, 1216, 597, 1198, 597], "text": "a"}, {"boundingBox": [1221, 563, 1283, 563, 1285, 596, 1224, 597], "text": "new"}, {"boundingBox": [1292, 563, 1434, 564, 1437, 595, 1295, 596], "text": "progestin"}]}, {"boundingBox": [208, 598, 1459, 597, 1460, 636, 209, 637], "text": "combined with the standard dose of Premarin into the US market. The registration of", "words": [{"boundingBox": [210, 601, 352, 600, 352, 636, 209, 636], "text": "combined"}, {"boundingBox": [359, 600, 422, 600, 421, 635, 359, 636], "text": "with"}, {"boundingBox": [429, 600, 478, 600, 477, 635, 428, 635], "text": "the"}, {"boundingBox": [485, 600, 622, 599, 622, 635, 484, 635], "text": "standard"}, {"boundingBox": [631, 599, 699, 599, 699, 635, 631, 635], "text": "dose"}, {"boundingBox": [706, 599, 736, 599, 736, 635, 706, 635], "text": "of"}, {"boundingBox": [743, 599, 878, 599, 878, 635, 743, 635], "text": "Premarin"}, {"boundingBox": [885, 599, 941, 599, 941, 635, 885, 635], "text": "into"}, {"boundingBox": [948, 599, 999, 598, 999, 635, 948, 635], "text": "the"}, {"boundingBox": [1006, 598, 1053, 598, 1053, 635, 1006, 635], "text": "US"}, {"boundingBox": [1060, 598, 1178, 598, 1179, 636, 1060, 635], "text": "market."}, {"boundingBox": [1185, 598, 1241, 598, 1242, 636, 1186, 636], "text": "The"}, {"boundingBox": [1248, 598, 1416, 598, 1416, 636, 1249, 636], "text": "registration"}, {"boundingBox": [1423, 598, 1458, 598, 1458, 636, 1423, 636], "text": "of"}]}, {"boundingBox": [205, 636, 1451, 637, 1450, 674, 204, 673], "text": "this product will extend the Premarin family to include new formulations containing a", "words": [{"boundingBox": [207, 637, 260, 638, 258, 674, 205, 674], "text": "this"}, {"boundingBox": [267, 638, 382, 638, 380, 674, 265, 674], "text": "product"}, {"boundingBox": [389, 638, 439, 638, 437, 674, 387, 674], "text": "will"}, {"boundingBox": [446, 638, 546, 638, 545, 674, 444, 674], "text": "extend"}, {"boundingBox": [553, 638, 604, 639, 602, 674, 552, 674], "text": "the"}, {"boundingBox": [611, 639, 747, 639, 746, 674, 609, 674], "text": "Premarin"}, {"boundingBox": [754, 639, 842, 639, 842, 674, 753, 674], "text": "family"}, {"boundingBox": [850, 639, 878, 639, 878, 674, 849, 674], "text": "to"}, {"boundingBox": [885, 639, 993, 639, 993, 674, 885, 674], "text": "include"}, {"boundingBox": [1000, 639, 1062, 639, 1062, 674, 1000, 674], "text": "new"}, {"boundingBox": [1072, 639, 1258, 639, 1258, 674, 1072, 674], "text": "formulations"}, {"boundingBox": [1265, 639, 1420, 639, 1421, 673, 1266, 674], "text": "containing"}, {"boundingBox": [1427, 639, 1449, 639, 1450, 673, 1428, 673], "text": "a"}]}, {"boundingBox": [207, 678, 1450, 677, 1450, 712, 208, 713], "text": "\"next generation\" progestin with a desirable clinical profile (e.g. competitive bleeding", "words": [{"boundingBox": [208, 678, 284, 678, 284, 713, 208, 713], "text": "\"next"}, {"boundingBox": [290, 678, 461, 679, 461, 713, 291, 713], "text": "generation\""}, {"boundingBox": [468, 679, 608, 679, 608, 713, 468, 713], "text": "progestin"}, {"boundingBox": [615, 679, 677, 680, 677, 713, 615, 713], "text": "with"}, {"boundingBox": [684, 680, 707, 680, 707, 713, 684, 713], "text": "a"}, {"boundingBox": [716, 680, 850, 680, 850, 713, 716, 713], "text": "desirable"}, {"boundingBox": [857, 680, 958, 680, 958, 713, 856, 713], "text": "clinical"}, {"boundingBox": [965, 680, 1059, 680, 1059, 713, 965, 713], "text": "profile"}, {"boundingBox": [1066, 680, 1135, 679, 1135, 713, 1066, 713], "text": "(e.g."}, {"boundingBox": [1142, 679, 1313, 679, 1312, 713, 1142, 713], "text": "competitive"}, {"boundingBox": [1320, 679, 1449, 678, 1447, 713, 1319, 713], "text": "bleeding"}]}, {"boundingBox": [204, 716, 1174, 715, 1175, 751, 205, 753], "text": "profile, positive impact on mood and Qol, good weight tolerance).", "words": [{"boundingBox": [206, 718, 308, 717, 308, 753, 205, 753], "text": "profile,"}, {"boundingBox": [315, 717, 432, 717, 431, 752, 315, 753], "text": "positive"}, {"boundingBox": [439, 717, 541, 716, 540, 751, 438, 752], "text": "impact"}, {"boundingBox": [548, 716, 585, 716, 584, 751, 547, 751], "text": "on"}, {"boundingBox": [592, 716, 681, 716, 680, 751, 591, 751], "text": "mood"}, {"boundingBox": [688, 716, 746, 716, 745, 751, 687, 751], "text": "and"}, {"boundingBox": [753, 716, 828, 716, 826, 751, 752, 751], "text": "Qol,"}, {"boundingBox": [835, 716, 909, 716, 907, 751, 833, 751], "text": "good"}, {"boundingBox": [916, 716, 1016, 716, 1014, 752, 914, 751], "text": "weight"}, {"boundingBox": [1023, 716, 1175, 717, 1172, 753, 1021, 752], "text": "tolerance)."}]}, {"boundingBox": [204, 794, 1408, 793, 1409, 827, 205, 828], "text": "However, the early termination of the HT subset of WHI and the publication of the", "words": [{"boundingBox": [207, 795, 350, 795, 351, 827, 208, 826], "text": "However,"}, {"boundingBox": [357, 795, 406, 796, 406, 828, 357, 827], "text": "the"}, {"boundingBox": [414, 796, 488, 796, 488, 828, 415, 828], "text": "early"}, {"boundingBox": [494, 796, 660, 796, 661, 829, 495, 828], "text": "termination"}, {"boundingBox": [668, 796, 699, 796, 700, 829, 669, 829], "text": "of"}, {"boundingBox": [705, 796, 754, 796, 755, 829, 706, 829], "text": "the"}, {"boundingBox": [760, 796, 809, 796, 810, 829, 761, 829], "text": "HT"}, {"boundingBox": [815, 796, 916, 796, 917, 829, 817, 829], "text": "subset"}, {"boundingBox": [922, 795, 953, 795, 954, 829, 923, 829], "text": "of"}, {"boundingBox": [959, 795, 1029, 795, 1030, 828, 960, 829], "text": "WHI"}, {"boundingBox": [1035, 795, 1092, 795, 1093, 828, 1036, 828], "text": "and"}, {"boundingBox": [1098, 795, 1147, 795, 1149, 828, 1099, 828], "text": "the"}, {"boundingBox": [1153, 795, 1315, 794, 1317, 827, 1155, 828], "text": "publication"}, {"boundingBox": [1324, 794, 1354, 794, 1356, 826, 1325, 827], "text": "of"}, {"boundingBox": [1360, 794, 1408, 794, 1409, 826, 1362, 826], "text": "the"}]}, {"boundingBox": [209, 830, 1465, 831, 1464, 866, 208, 865], "text": "results have led Wyeth to reassess the risks and benefits of hormone therapy, and to", "words": [{"boundingBox": [211, 831, 306, 832, 305, 865, 209, 865], "text": "results"}, {"boundingBox": [313, 832, 388, 832, 387, 865, 311, 865], "text": "have"}, {"boundingBox": [395, 832, 444, 832, 442, 865, 394, 865], "text": "led"}, {"boundingBox": [451, 832, 548, 832, 547, 864, 449, 865], "text": "Wyeth"}, {"boundingBox": [555, 832, 584, 832, 582, 864, 554, 864], "text": "to"}, {"boundingBox": [591, 832, 728, 832, 727, 864, 589, 864], "text": "reassess"}, {"boundingBox": [735, 832, 782, 832, 780, 865, 733, 864], "text": "the"}, {"boundingBox": [788, 832, 862, 832, 860, 865, 787, 865], "text": "risks"}, {"boundingBox": [868, 832, 926, 832, 925, 865, 867, 865], "text": "and"}, {"boundingBox": [933, 832, 1053, 832, 1051, 865, 931, 865], "text": "benefits"}, {"boundingBox": [1059, 832, 1088, 832, 1087, 865, 1058, 865], "text": "of"}, {"boundingBox": [1095, 832, 1231, 832, 1229, 866, 1093, 865], "text": "hormone"}, {"boundingBox": [1237, 832, 1362, 831, 1360, 867, 1236, 866], "text": "therapy,"}, {"boundingBox": [1368, 831, 1426, 831, 1424, 867, 1367, 867], "text": "and"}, {"boundingBox": [1433, 831, 1464, 831, 1462, 867, 1431, 867], "text": "to"}]}, {"boundingBox": [207, 868, 1427, 869, 1426, 907, 206, 906], "text": "review the strategy for its HRT franchise. If the strategy has been refocused on the", "words": [{"boundingBox": [208, 870, 300, 870, 299, 905, 207, 904], "text": "review"}, {"boundingBox": [312, 870, 364, 869, 363, 906, 311, 905], "text": "the"}, {"boundingBox": [370, 869, 490, 869, 489, 906, 369, 906], "text": "strategy"}, {"boundingBox": [497, 869, 537, 869, 537, 907, 496, 906], "text": "for"}, {"boundingBox": [544, 869, 580, 869, 580, 907, 543, 907], "text": "its"}, {"boundingBox": [587, 869, 659, 869, 659, 907, 586, 907], "text": "HRT"}, {"boundingBox": [666, 869, 813, 869, 812, 907, 665, 907], "text": "franchise."}, {"boundingBox": [820, 869, 840, 869, 839, 907, 819, 907], "text": "If"}, {"boundingBox": [847, 869, 896, 869, 896, 907, 846, 907], "text": "the"}, {"boundingBox": [903, 869, 1023, 869, 1022, 907, 903, 907], "text": "strategy"}, {"boundingBox": [1030, 869, 1086, 869, 1085, 907, 1029, 907], "text": "has"}, {"boundingBox": [1093, 869, 1170, 870, 1169, 906, 1092, 907], "text": "been"}, {"boundingBox": [1176, 870, 1328, 870, 1327, 905, 1176, 906], "text": "refocused"}, {"boundingBox": [1334, 870, 1373, 870, 1372, 905, 1334, 905], "text": "on"}, {"boundingBox": [1379, 871, 1427, 871, 1427, 905, 1379, 905], "text": "the"}]}, {"boundingBox": [206, 905, 1468, 903, 1469, 943, 207, 944], "text": "short-term benefits of hormone therapy, several variables may still affect the future of", "words": [{"boundingBox": [209, 907, 352, 908, 353, 943, 209, 941], "text": "short-term"}, {"boundingBox": [366, 908, 488, 908, 489, 944, 366, 943], "text": "benefits"}, {"boundingBox": [495, 908, 525, 908, 525, 944, 496, 944], "text": "of"}, {"boundingBox": [532, 908, 665, 909, 666, 945, 532, 944], "text": "hormone"}, {"boundingBox": [672, 909, 795, 909, 795, 945, 673, 945], "text": "therapy,"}, {"boundingBox": [801, 909, 910, 908, 911, 945, 802, 945], "text": "several"}, {"boundingBox": [917, 908, 1053, 908, 1054, 945, 918, 945], "text": "variables"}, {"boundingBox": [1060, 908, 1128, 907, 1129, 944, 1061, 945], "text": "may"}, {"boundingBox": [1135, 907, 1185, 907, 1186, 944, 1136, 944], "text": "still"}, {"boundingBox": [1191, 907, 1275, 906, 1277, 944, 1193, 944], "text": "affect"}, {"boundingBox": [1282, 906, 1332, 906, 1334, 943, 1284, 944], "text": "the"}, {"boundingBox": [1339, 906, 1425, 905, 1427, 943, 1340, 943], "text": "future"}, {"boundingBox": [1432, 905, 1466, 904, 1468, 942, 1434, 943], "text": "of"}]}, {"boundingBox": [207, 944, 1466, 946, 1465, 982, 206, 980], "text": "Premarin family, including the generalization of WHI findings to all estrogen/progestin", "words": [{"boundingBox": [208, 945, 344, 946, 343, 980, 207, 980], "text": "Premarin"}, {"boundingBox": [350, 946, 448, 946, 448, 981, 350, 980], "text": "family,"}, {"boundingBox": [455, 946, 591, 946, 591, 981, 455, 981], "text": "including"}, {"boundingBox": [598, 946, 649, 946, 649, 982, 597, 982], "text": "the"}, {"boundingBox": [656, 946, 863, 946, 863, 982, 655, 982], "text": "generalization"}, {"boundingBox": [872, 946, 901, 946, 900, 982, 871, 982], "text": "of"}, {"boundingBox": [908, 946, 975, 946, 974, 983, 907, 982], "text": "WHI"}, {"boundingBox": [981, 946, 1100, 946, 1099, 983, 981, 983], "text": "findings"}, {"boundingBox": [1106, 946, 1137, 946, 1137, 983, 1105, 983], "text": "to"}, {"boundingBox": [1144, 946, 1182, 946, 1181, 983, 1143, 983], "text": "all"}, {"boundingBox": [1189, 946, 1465, 947, 1464, 983, 1188, 983], "text": "estrogen/progestin"}]}, {"boundingBox": [206, 981, 1482, 983, 1481, 1021, 205, 1020], "text": "formulations, the Premarin dose effect, and the progestin responsibility. In this context,", "words": [{"boundingBox": [207, 983, 401, 984, 400, 1020, 206, 1019], "text": "formulations,"}, {"boundingBox": [408, 984, 455, 984, 454, 1020, 407, 1020], "text": "the"}, {"boundingBox": [462, 984, 604, 985, 602, 1021, 461, 1020], "text": "Premarin"}, {"boundingBox": [615, 985, 684, 985, 682, 1021, 614, 1021], "text": "dose"}, {"boundingBox": [691, 985, 783, 985, 781, 1022, 689, 1021], "text": "effect,"}, {"boundingBox": [790, 985, 846, 985, 845, 1022, 788, 1022], "text": "and"}, {"boundingBox": [853, 985, 901, 985, 899, 1022, 852, 1022], "text": "the"}, {"boundingBox": [908, 985, 1049, 985, 1048, 1022, 906, 1022], "text": "progestin"}, {"boundingBox": [1056, 985, 1261, 984, 1260, 1022, 1055, 1022], "text": "responsibility."}, {"boundingBox": [1268, 984, 1299, 984, 1297, 1022, 1267, 1022], "text": "In"}, {"boundingBox": [1306, 984, 1360, 984, 1359, 1021, 1304, 1022], "text": "this"}, {"boundingBox": [1367, 984, 1481, 983, 1479, 1021, 1366, 1021], "text": "context,"}]}, {"boundingBox": [206, 1021, 1483, 1021, 1484, 1059, 207, 1060], "text": "Premarin/Trimegestone can be seen as an alternative to MPA-based HT formulations.", "words": [{"boundingBox": [208, 1024, 559, 1026, 557, 1059, 207, 1059], "text": "Premarin/Trimegestone"}, {"boundingBox": [566, 1026, 620, 1026, 618, 1059, 564, 1059], "text": "can"}, {"boundingBox": [627, 1026, 670, 1026, 668, 1059, 625, 1059], "text": "be"}, {"boundingBox": [677, 1026, 752, 1026, 749, 1059, 675, 1059], "text": "seen"}, {"boundingBox": [759, 1026, 795, 1026, 792, 1059, 756, 1059], "text": "as"}, {"boundingBox": [802, 1026, 842, 1026, 840, 1059, 799, 1059], "text": "an"}, {"boundingBox": [849, 1026, 1003, 1025, 1000, 1059, 847, 1059], "text": "alternative"}, {"boundingBox": [1010, 1025, 1042, 1025, 1039, 1060, 1007, 1059], "text": "to"}, {"boundingBox": [1049, 1025, 1225, 1024, 1222, 1060, 1046, 1060], "text": "MPA-based"}, {"boundingBox": [1232, 1024, 1280, 1023, 1276, 1060, 1229, 1060], "text": "HT"}, {"boundingBox": [1287, 1023, 1484, 1021, 1480, 1061, 1283, 1060], "text": "formulations."}]}, {"boundingBox": [203, 1100, 1450, 1099, 1451, 1136, 204, 1137], "text": "Depending on the current and future performance of Premarin on the US market, as", "words": [{"boundingBox": [209, 1100, 372, 1101, 368, 1136, 204, 1136], "text": "Depending"}, {"boundingBox": [379, 1101, 417, 1101, 413, 1137, 375, 1136], "text": "on"}, {"boundingBox": [424, 1101, 473, 1101, 470, 1137, 420, 1137], "text": "the"}, {"boundingBox": [480, 1101, 589, 1101, 586, 1137, 477, 1137], "text": "current"}, {"boundingBox": [596, 1101, 651, 1101, 648, 1137, 593, 1137], "text": "and"}, {"boundingBox": [658, 1101, 745, 1101, 742, 1137, 655, 1137], "text": "future"}, {"boundingBox": [752, 1101, 941, 1101, 939, 1137, 749, 1137], "text": "performance"}, {"boundingBox": [948, 1101, 979, 1101, 977, 1137, 946, 1137], "text": "of"}, {"boundingBox": [986, 1101, 1123, 1101, 1122, 1137, 984, 1137], "text": "Premarin"}, {"boundingBox": [1130, 1101, 1171, 1101, 1169, 1137, 1129, 1137], "text": "on"}, {"boundingBox": [1178, 1101, 1227, 1101, 1226, 1136, 1176, 1137], "text": "the"}, {"boundingBox": [1234, 1101, 1282, 1100, 1280, 1136, 1233, 1136], "text": "US"}, {"boundingBox": [1289, 1100, 1402, 1100, 1401, 1136, 1288, 1136], "text": "market,"}, {"boundingBox": [1409, 1100, 1449, 1100, 1449, 1136, 1408, 1136], "text": "as"}]}, {"boundingBox": [207, 1139, 1467, 1137, 1468, 1173, 208, 1175], "text": "well as new perspective offered by trimegestone, there might be a need for Phase IV", "words": [{"boundingBox": [208, 1141, 268, 1141, 269, 1173, 209, 1172], "text": "well"}, {"boundingBox": [274, 1141, 309, 1141, 310, 1173, 275, 1173], "text": "as"}, {"boundingBox": [315, 1141, 375, 1141, 376, 1173, 316, 1173], "text": "new"}, {"boundingBox": [388, 1141, 561, 1141, 562, 1175, 389, 1174], "text": "perspective"}, {"boundingBox": [570, 1141, 675, 1141, 676, 1175, 571, 1175], "text": "offered"}, {"boundingBox": [681, 1141, 718, 1141, 719, 1175, 682, 1175], "text": "by"}, {"boundingBox": [725, 1141, 931, 1141, 932, 1175, 726, 1175], "text": "trimegestone,"}, {"boundingBox": [937, 1141, 1016, 1140, 1017, 1175, 939, 1175], "text": "there"}, {"boundingBox": [1022, 1140, 1107, 1140, 1108, 1174, 1023, 1175], "text": "might"}, {"boundingBox": [1113, 1140, 1152, 1140, 1154, 1174, 1114, 1174], "text": "be"}, {"boundingBox": [1161, 1140, 1181, 1140, 1183, 1174, 1162, 1174], "text": "a"}, {"boundingBox": [1187, 1139, 1266, 1139, 1267, 1173, 1189, 1174], "text": "need"}, {"boundingBox": [1272, 1139, 1316, 1139, 1317, 1173, 1273, 1173], "text": "for"}, {"boundingBox": [1322, 1139, 1417, 1138, 1418, 1172, 1323, 1173], "text": "Phase"}, {"boundingBox": [1423, 1138, 1456, 1138, 1457, 1172, 1424, 1172], "text": "IV"}]}, {"boundingBox": [200, 1178, 1492, 1178, 1491, 1213, 199, 1212], "text": "studies. Such a program should further assess the benefits of Trimegestone compared", "words": [{"boundingBox": [206, 1178, 326, 1178, 327, 1213, 208, 1212], "text": "studies."}, {"boundingBox": [333, 1178, 409, 1179, 411, 1213, 334, 1213], "text": "Such"}, {"boundingBox": [416, 1179, 436, 1179, 438, 1213, 417, 1213], "text": "a"}, {"boundingBox": [443, 1179, 563, 1179, 564, 1213, 444, 1213], "text": "program"}, {"boundingBox": [579, 1179, 678, 1180, 679, 1213, 580, 1213], "text": "should"}, {"boundingBox": [685, 1180, 784, 1180, 785, 1213, 686, 1213], "text": "further"}, {"boundingBox": [791, 1180, 897, 1180, 897, 1213, 791, 1213], "text": "assess"}, {"boundingBox": [904, 1180, 951, 1180, 951, 1213, 904, 1213], "text": "the"}, {"boundingBox": [958, 1180, 1080, 1180, 1080, 1212, 958, 1213], "text": "benefits"}, {"boundingBox": [1086, 1180, 1120, 1180, 1120, 1212, 1087, 1212], "text": "of"}, {"boundingBox": [1127, 1180, 1330, 1180, 1330, 1212, 1127, 1212], "text": "Trimegestone"}, {"boundingBox": [1337, 1180, 1490, 1180, 1490, 1211, 1337, 1212], "text": "compared"}]}, {"boundingBox": [208, 1216, 1393, 1215, 1394, 1250, 209, 1251], "text": "to other progestins, and provide head-to-head comparisons with other marketed", "words": [{"boundingBox": [210, 1216, 238, 1216, 237, 1252, 209, 1252], "text": "to"}, {"boundingBox": [245, 1216, 323, 1216, 322, 1252, 244, 1252], "text": "other"}, {"boundingBox": [330, 1216, 497, 1216, 496, 1251, 329, 1252], "text": "progestins,"}, {"boundingBox": [504, 1216, 561, 1216, 560, 1251, 503, 1251], "text": "and"}, {"boundingBox": [568, 1216, 678, 1217, 677, 1251, 567, 1251], "text": "provide"}, {"boundingBox": [685, 1217, 888, 1217, 887, 1251, 684, 1251], "text": "head-to-head"}, {"boundingBox": [895, 1217, 1085, 1217, 1085, 1250, 894, 1251], "text": "comparisons"}, {"boundingBox": [1092, 1217, 1153, 1218, 1153, 1250, 1092, 1250], "text": "with"}, {"boundingBox": [1160, 1218, 1238, 1218, 1238, 1250, 1160, 1250], "text": "other"}, {"boundingBox": [1245, 1218, 1393, 1218, 1393, 1249, 1245, 1250], "text": "marketed"}]}, {"boundingBox": [206, 1254, 1469, 1253, 1470, 1290, 207, 1291], "text": "formulations, including Femhrt (for US market), Activella (for US and Ex-US markets),", "words": [{"boundingBox": [207, 1255, 397, 1254, 398, 1291, 209, 1290], "text": "formulations,"}, {"boundingBox": [404, 1254, 541, 1254, 542, 1291, 405, 1291], "text": "including"}, {"boundingBox": [548, 1254, 656, 1254, 657, 1292, 549, 1291], "text": "Femhrt"}, {"boundingBox": [662, 1254, 715, 1254, 716, 1292, 664, 1292], "text": "(for"}, {"boundingBox": [722, 1254, 768, 1254, 769, 1292, 723, 1292], "text": "US"}, {"boundingBox": [774, 1254, 900, 1254, 901, 1292, 776, 1292], "text": "market),"}, {"boundingBox": [907, 1254, 1035, 1254, 1036, 1291, 908, 1292], "text": "Activella"}, {"boundingBox": [1042, 1254, 1095, 1254, 1096, 1291, 1043, 1291], "text": "(for"}, {"boundingBox": [1101, 1254, 1150, 1254, 1150, 1291, 1102, 1291], "text": "US"}, {"boundingBox": [1156, 1254, 1216, 1254, 1217, 1291, 1157, 1291], "text": "and"}, {"boundingBox": [1223, 1254, 1319, 1255, 1320, 1290, 1224, 1291], "text": "Ex-US"}, {"boundingBox": [1326, 1255, 1467, 1255, 1468, 1289, 1327, 1290], "text": "markets),"}]}, {"boundingBox": [209, 1293, 1449, 1295, 1448, 1330, 208, 1329], "text": "and Tibolone (mainly for Ex-US markets). In addition, this program is focused on the", "words": [{"boundingBox": [209, 1295, 265, 1295, 266, 1328, 210, 1328], "text": "and"}, {"boundingBox": [274, 1295, 403, 1294, 403, 1329, 274, 1328], "text": "Tibolone"}, {"boundingBox": [409, 1294, 519, 1294, 519, 1330, 409, 1329], "text": "(mainly"}, {"boundingBox": [525, 1294, 569, 1294, 568, 1330, 525, 1330], "text": "for"}, {"boundingBox": [575, 1294, 672, 1294, 671, 1330, 575, 1330], "text": "Ex-US"}, {"boundingBox": [678, 1294, 820, 1295, 819, 1331, 678, 1330], "text": "markets)."}, {"boundingBox": [827, 1295, 859, 1295, 858, 1331, 826, 1331], "text": "In"}, {"boundingBox": [866, 1295, 993, 1295, 991, 1330, 864, 1331], "text": "addition,"}, {"boundingBox": [999, 1295, 1055, 1295, 1053, 1330, 998, 1330], "text": "this"}, {"boundingBox": [1061, 1295, 1180, 1296, 1178, 1330, 1060, 1330], "text": "program"}, {"boundingBox": [1195, 1296, 1223, 1296, 1221, 1330, 1193, 1330], "text": "is"}, {"boundingBox": [1229, 1296, 1352, 1296, 1350, 1329, 1227, 1330], "text": "focused"}, {"boundingBox": [1358, 1296, 1397, 1297, 1395, 1328, 1356, 1329], "text": "on"}, {"boundingBox": [1404, 1297, 1449, 1297, 1446, 1328, 1401, 1328], "text": "the"}]}, {"boundingBox": [207, 1329, 1445, 1332, 1444, 1370, 206, 1367], "text": "short-term benefits of hormone therapy (vasomotor symptoms and impact on mood,", "words": [{"boundingBox": [210, 1330, 354, 1331, 351, 1368, 207, 1367], "text": "short-term"}, {"boundingBox": [369, 1331, 489, 1331, 486, 1368, 366, 1368], "text": "benefits"}, {"boundingBox": [496, 1331, 525, 1331, 522, 1369, 493, 1368], "text": "of"}, {"boundingBox": [532, 1331, 664, 1331, 661, 1369, 529, 1369], "text": "hormone"}, {"boundingBox": [671, 1331, 787, 1332, 784, 1369, 668, 1369], "text": "therapy"}, {"boundingBox": [794, 1332, 962, 1332, 959, 1370, 791, 1369], "text": "(vasomotor"}, {"boundingBox": [969, 1332, 1126, 1332, 1123, 1369, 966, 1370], "text": "symptoms"}, {"boundingBox": [1133, 1332, 1188, 1333, 1185, 1369, 1130, 1369], "text": "and"}, {"boundingBox": [1195, 1333, 1299, 1333, 1296, 1369, 1192, 1369], "text": "impact"}, {"boundingBox": [1306, 1333, 1342, 1333, 1339, 1369, 1303, 1369], "text": "on"}, {"boundingBox": [1349, 1333, 1443, 1333, 1440, 1369, 1346, 1369], "text": "mood,"}]}, {"boundingBox": [205, 1369, 556, 1368, 557, 1406, 206, 1407], "text": "sleep and quality of life)", "words": [{"boundingBox": [209, 1371, 290, 1370, 289, 1406, 208, 1406], "text": "sleep"}, {"boundingBox": [297, 1370, 357, 1370, 356, 1406, 296, 1406], "text": "and"}, {"boundingBox": [364, 1370, 460, 1369, 460, 1407, 363, 1406], "text": "quality"}, {"boundingBox": [467, 1369, 497, 1369, 497, 1407, 467, 1407], "text": "of"}, {"boundingBox": [504, 1369, 557, 1369, 557, 1407, 504, 1407], "text": "life)"}]}, {"boundingBox": [204, 1446, 1470, 1445, 1471, 1482, 205, 1483], "text": "Based on preclinical data, TMG has been shown to have a lower impact on the GABA", "words": [{"boundingBox": [207, 1446, 303, 1446, 302, 1483, 205, 1483], "text": "Based"}, {"boundingBox": [311, 1447, 349, 1447, 347, 1483, 309, 1483], "text": "on"}, {"boundingBox": [357, 1447, 514, 1447, 512, 1483, 355, 1483], "text": "preclinical"}, {"boundingBox": [521, 1447, 593, 1447, 592, 1483, 519, 1483], "text": "data,"}, {"boundingBox": [600, 1447, 673, 1447, 671, 1483, 599, 1483], "text": "TMG"}, {"boundingBox": [680, 1447, 736, 1447, 734, 1483, 679, 1483], "text": "has"}, {"boundingBox": [743, 1447, 820, 1447, 819, 1483, 741, 1483], "text": "been"}, {"boundingBox": [827, 1447, 924, 1447, 923, 1483, 826, 1483], "text": "shown"}, {"boundingBox": [931, 1447, 960, 1447, 959, 1483, 930, 1483], "text": "to"}, {"boundingBox": [967, 1447, 1045, 1447, 1044, 1483, 966, 1483], "text": "have"}, {"boundingBox": [1052, 1447, 1069, 1447, 1068, 1483, 1051, 1483], "text": "a"}, {"boundingBox": [1076, 1447, 1158, 1447, 1157, 1483, 1075, 1483], "text": "lower"}, {"boundingBox": [1165, 1447, 1269, 1447, 1268, 1482, 1165, 1483], "text": "impact"}, {"boundingBox": [1277, 1447, 1315, 1447, 1314, 1482, 1276, 1482], "text": "on"}, {"boundingBox": [1322, 1447, 1373, 1447, 1372, 1482, 1322, 1482], "text": "the"}, {"boundingBox": [1380, 1447, 1470, 1447, 1469, 1482, 1380, 1482], "text": "GABA"}]}, {"boundingBox": [206, 1487, 1492, 1485, 1493, 1522, 207, 1524], "text": "receptors than progesterone or other progestins, suggesting a more favorable effect on", "words": [{"boundingBox": [207, 1488, 348, 1489, 348, 1522, 207, 1520], "text": "receptors"}, {"boundingBox": [354, 1489, 422, 1490, 423, 1522, 355, 1522], "text": "than"}, {"boundingBox": [429, 1490, 629, 1491, 630, 1523, 429, 1522], "text": "progesterone"}, {"boundingBox": [635, 1491, 667, 1491, 668, 1524, 636, 1524], "text": "or"}, {"boundingBox": [674, 1491, 752, 1491, 754, 1524, 675, 1524], "text": "other"}, {"boundingBox": [759, 1491, 925, 1491, 926, 1524, 760, 1524], "text": "progestins,"}, {"boundingBox": [931, 1491, 1095, 1490, 1097, 1523, 933, 1524], "text": "suggesting"}, {"boundingBox": [1102, 1490, 1121, 1490, 1123, 1523, 1103, 1523], "text": "a"}, {"boundingBox": [1127, 1490, 1208, 1489, 1210, 1523, 1129, 1523], "text": "more"}, {"boundingBox": [1215, 1489, 1355, 1488, 1357, 1521, 1216, 1522], "text": "favorable"}, {"boundingBox": [1362, 1488, 1447, 1486, 1449, 1520, 1364, 1521], "text": "effect"}, {"boundingBox": [1453, 1486, 1489, 1486, 1492, 1520, 1455, 1520], "text": "on"}]}, {"boundingBox": [204, 1527, 1455, 1526, 1456, 1560, 205, 1561], "text": "mood or sleep. In clinical trials, TMG, either combined with estradiol or Premarin, has", "words": [{"boundingBox": [207, 1528, 294, 1528, 292, 1560, 205, 1559], "text": "mood"}, {"boundingBox": [300, 1528, 334, 1528, 331, 1560, 298, 1560], "text": "or"}, {"boundingBox": [340, 1528, 431, 1528, 429, 1560, 338, 1560], "text": "sleep."}, {"boundingBox": [437, 1528, 466, 1528, 464, 1561, 435, 1560], "text": "In"}, {"boundingBox": [474, 1528, 578, 1528, 576, 1561, 473, 1561], "text": "clinical"}, {"boundingBox": [584, 1528, 671, 1528, 670, 1561, 582, 1561], "text": "trials,"}, {"boundingBox": [677, 1528, 760, 1528, 759, 1561, 676, 1561], "text": "TMG,"}, {"boundingBox": [766, 1528, 851, 1528, 850, 1561, 765, 1561], "text": "either"}, {"boundingBox": [857, 1528, 1004, 1528, 1004, 1561, 856, 1561], "text": "combined"}, {"boundingBox": [1011, 1528, 1071, 1528, 1070, 1561, 1010, 1561], "text": "with"}, {"boundingBox": [1079, 1528, 1209, 1528, 1209, 1560, 1078, 1561], "text": "estradiol"}, {"boundingBox": [1216, 1528, 1249, 1528, 1249, 1560, 1215, 1560], "text": "or"}, {"boundingBox": [1255, 1528, 1402, 1527, 1402, 1559, 1255, 1560], "text": "Premarin,"}, {"boundingBox": [1408, 1527, 1454, 1527, 1454, 1558, 1408, 1559], "text": "has"}]}, {"boundingBox": [206, 1563, 1433, 1561, 1434, 1597, 207, 1599], "text": "shown a positive impact on quality of life. When combined with estradiol, TMG was", "words": [{"boundingBox": [209, 1564, 306, 1563, 304, 1599, 207, 1600], "text": "shown"}, {"boundingBox": [313, 1563, 332, 1563, 330, 1599, 311, 1599], "text": "a"}, {"boundingBox": [339, 1563, 455, 1563, 453, 1598, 337, 1599], "text": "positive"}, {"boundingBox": [462, 1563, 564, 1563, 562, 1598, 460, 1598], "text": "impact"}, {"boundingBox": [571, 1563, 611, 1563, 610, 1598, 569, 1598], "text": "on"}, {"boundingBox": [618, 1563, 715, 1563, 714, 1598, 617, 1598], "text": "quality"}, {"boundingBox": [722, 1563, 751, 1563, 749, 1597, 721, 1598], "text": "of"}, {"boundingBox": [758, 1563, 812, 1563, 811, 1597, 757, 1597], "text": "life."}, {"boundingBox": [819, 1563, 909, 1563, 908, 1597, 818, 1597], "text": "When"}, {"boundingBox": [916, 1563, 1063, 1563, 1062, 1597, 915, 1597], "text": "combined"}, {"boundingBox": [1070, 1563, 1132, 1563, 1131, 1597, 1069, 1597], "text": "with"}, {"boundingBox": [1139, 1563, 1281, 1563, 1280, 1597, 1138, 1597], "text": "estradiol,"}, {"boundingBox": [1288, 1563, 1359, 1563, 1358, 1598, 1287, 1597], "text": "TMG"}, {"boundingBox": [1368, 1563, 1432, 1563, 1431, 1598, 1367, 1598], "text": "was"}]}, {"boundingBox": [205, 1600, 1327, 1599, 1328, 1636, 206, 1637], "text": "significantly better than Activella for several domains of the Women's Health", "words": [{"boundingBox": [207, 1600, 380, 1601, 379, 1638, 206, 1638], "text": "significantly"}, {"boundingBox": [387, 1601, 474, 1601, 473, 1638, 386, 1638], "text": "better"}, {"boundingBox": [481, 1601, 551, 1601, 550, 1638, 480, 1638], "text": "than"}, {"boundingBox": [558, 1601, 682, 1601, 681, 1638, 557, 1638], "text": "Activella"}, {"boundingBox": [689, 1601, 731, 1601, 730, 1638, 688, 1638], "text": "for"}, {"boundingBox": [738, 1601, 855, 1601, 854, 1637, 737, 1638], "text": "several"}, {"boundingBox": [862, 1601, 983, 1601, 982, 1637, 861, 1637], "text": "domains"}, {"boundingBox": [991, 1601, 1020, 1601, 1019, 1637, 990, 1637], "text": "of"}, {"boundingBox": [1028, 1601, 1075, 1601, 1074, 1637, 1027, 1637], "text": "the"}, {"boundingBox": [1082, 1601, 1223, 1600, 1222, 1637, 1081, 1637], "text": "Women's"}, {"boundingBox": [1231, 1600, 1327, 1600, 1326, 1637, 1229, 1637], "text": "Health"}]}, {"boundingBox": [208, 1638, 1392, 1640, 1391, 1676, 207, 1674], "text": "Questionnaire, including mood, sleep and sexual behavior. When combined with", "words": [{"boundingBox": [208, 1638, 424, 1639, 423, 1675, 208, 1674], "text": "Questionnaire,"}, {"boundingBox": [431, 1639, 566, 1640, 566, 1675, 431, 1675], "text": "including"}, {"boundingBox": [573, 1640, 670, 1640, 670, 1675, 573, 1675], "text": "mood,"}, {"boundingBox": [677, 1640, 758, 1640, 758, 1675, 677, 1675], "text": "sleep"}, {"boundingBox": [765, 1640, 824, 1640, 824, 1675, 765, 1675], "text": "and"}, {"boundingBox": [831, 1640, 926, 1640, 926, 1675, 831, 1675], "text": "sexual"}, {"boundingBox": [933, 1640, 1075, 1641, 1076, 1675, 933, 1675], "text": "behavior."}, {"boundingBox": [1082, 1641, 1172, 1641, 1173, 1675, 1083, 1675], "text": "When"}, {"boundingBox": [1179, 1641, 1326, 1641, 1327, 1675, 1180, 1675], "text": "combined"}, {"boundingBox": [1333, 1641, 1390, 1641, 1391, 1675, 1334, 1675], "text": "with"}]}, {"boundingBox": [204, 1676, 1416, 1678, 1415, 1714, 203, 1712], "text": "Premarin, TMG showed a significant improvement compared to placebo for sleep,", "words": [{"boundingBox": [207, 1677, 356, 1678, 355, 1712, 206, 1713], "text": "Premarin,"}, {"boundingBox": [364, 1678, 435, 1678, 434, 1712, 362, 1712], "text": "TMG"}, {"boundingBox": [444, 1678, 563, 1679, 562, 1712, 443, 1712], "text": "showed"}, {"boundingBox": [570, 1679, 591, 1679, 590, 1712, 569, 1712], "text": "a"}, {"boundingBox": [598, 1679, 745, 1679, 744, 1712, 597, 1712], "text": "significant"}, {"boundingBox": [752, 1679, 949, 1679, 948, 1713, 751, 1712], "text": "improvement"}, {"boundingBox": [956, 1679, 1105, 1679, 1104, 1713, 955, 1713], "text": "compared"}, {"boundingBox": [1113, 1679, 1143, 1679, 1142, 1713, 1111, 1713], "text": "to"}, {"boundingBox": [1150, 1679, 1271, 1679, 1270, 1714, 1149, 1713], "text": "placebo"}, {"boundingBox": [1278, 1679, 1321, 1679, 1320, 1714, 1277, 1714], "text": "for"}, {"boundingBox": [1328, 1679, 1416, 1679, 1415, 1715, 1327, 1714], "text": "sleep,"}]}, {"boundingBox": [204, 1717, 1139, 1718, 1138, 1753, 203, 1752], "text": "memory/concentration, somatic problems and sexual behavior.", "words": [{"boundingBox": [206, 1719, 549, 1718, 550, 1754, 206, 1752], "text": "memory/concentration,"}, {"boundingBox": [556, 1718, 673, 1718, 673, 1754, 556, 1754], "text": "somatic"}, {"boundingBox": [680, 1718, 821, 1718, 821, 1754, 680, 1754], "text": "problems"}, {"boundingBox": [827, 1718, 884, 1718, 884, 1754, 828, 1754], "text": "and"}, {"boundingBox": [890, 1718, 988, 1719, 989, 1753, 891, 1754], "text": "sexual"}, {"boundingBox": [995, 1719, 1138, 1720, 1138, 1753, 995, 1753], "text": "behavior."}]}, {"boundingBox": [208, 1793, 1485, 1794, 1485, 1828, 207, 1828], "text": "In addition, TMG has shown in clinical trials a good weight tolerance both compared to", "words": [{"boundingBox": [208, 1794, 237, 1794, 237, 1829, 208, 1829], "text": "In"}, {"boundingBox": [244, 1794, 375, 1795, 375, 1829, 244, 1829], "text": "addition,"}, {"boundingBox": [382, 1795, 452, 1795, 452, 1829, 382, 1829], "text": "TMG"}, {"boundingBox": [461, 1795, 519, 1795, 520, 1829, 461, 1829], "text": "has"}, {"boundingBox": [526, 1795, 623, 1795, 623, 1829, 526, 1829], "text": "shown"}, {"boundingBox": [630, 1795, 659, 1795, 659, 1829, 630, 1829], "text": "in"}, {"boundingBox": [666, 1795, 768, 1795, 768, 1829, 666, 1829], "text": "clinical"}, {"boundingBox": [774, 1795, 849, 1795, 849, 1829, 775, 1829], "text": "trials"}, {"boundingBox": [856, 1795, 876, 1795, 876, 1829, 856, 1829], "text": "a"}, {"boundingBox": [883, 1795, 957, 1795, 957, 1829, 883, 1829], "text": "good"}, {"boundingBox": [964, 1795, 1064, 1795, 1063, 1829, 964, 1829], "text": "weight"}, {"boundingBox": [1070, 1795, 1213, 1795, 1212, 1829, 1070, 1829], "text": "tolerance"}, {"boundingBox": [1219, 1795, 1287, 1795, 1287, 1829, 1219, 1829], "text": "both"}, {"boundingBox": [1294, 1795, 1445, 1795, 1445, 1829, 1294, 1829], "text": "compared"}, {"boundingBox": [1452, 1795, 1483, 1794, 1483, 1829, 1452, 1829], "text": "to"}]}, {"boundingBox": [205, 1832, 730, 1832, 730, 1867, 206, 1868], "text": "placebo and compared to Activella.", "words": [{"boundingBox": [206, 1834, 326, 1834, 326, 1867, 206, 1869], "text": "placebo"}, {"boundingBox": [333, 1834, 392, 1834, 392, 1867, 333, 1867], "text": "and"}, {"boundingBox": [399, 1834, 549, 1833, 549, 1867, 399, 1867], "text": "compared"}, {"boundingBox": [556, 1833, 586, 1833, 586, 1867, 556, 1867], "text": "to"}, {"boundingBox": [592, 1833, 729, 1832, 729, 1868, 592, 1867], "text": "Activella."}]}, {"boundingBox": [205, 1904, 745, 1906, 744, 1946, 204, 1943], "text": "9.1 Studies under consideration", "words": [{"boundingBox": [205, 1904, 262, 1906, 263, 1943, 207, 1942], "text": "9.1"}, {"boundingBox": [287, 1907, 410, 1910, 411, 1945, 288, 1944], "text": "Studies"}, {"boundingBox": [417, 1910, 513, 1911, 515, 1946, 419, 1945], "text": "under"}, {"boundingBox": [521, 1911, 740, 1908, 742, 1944, 522, 1946], "text": "consideration"}]}, {"boundingBox": [199, 2069, 403, 2070, 403, 2107, 198, 2106], "text": "Confidential", "words": [{"boundingBox": [206, 2071, 403, 2070, 402, 2107, 207, 2107], "text": "Confidential"}]}, {"boundingBox": [803, 2069, 932, 2071, 931, 2105, 802, 2102], "text": "30 of 42", "words": [{"boundingBox": [807, 2071, 845, 2071, 846, 2102, 809, 2103], "text": "30"}, {"boundingBox": [854, 2071, 893, 2071, 893, 2103, 854, 2102], "text": "of"}, {"boundingBox": [902, 2071, 931, 2072, 930, 2105, 901, 2104], "text": "42"}]}, {"boundingBox": [21, 2201, 492, 2203, 491, 2233, 20, 2230], "text": "Confidential Pursuant to Confidentiality", "words": [{"boundingBox": [23, 2201, 166, 2202, 167, 2231, 23, 2231], "text": "Confidential"}, {"boundingBox": [172, 2202, 283, 2203, 284, 2232, 173, 2231], "text": "Pursuant"}, {"boundingBox": [289, 2203, 315, 2203, 316, 2232, 290, 2232], "text": "to"}, {"boundingBox": [321, 2203, 491, 2204, 492, 2234, 322, 2232], "text": "Confidentiality"}]}, {"boundingBox": [1430, 2206, 1685, 2205, 1686, 2233, 1431, 2234], "text": "KERZC001-000303", "words": [{"boundingBox": [1436, 2207, 1683, 2206, 1684, 2233, 1437, 2234], "text": "KERZC001-000303"}]}, {"boundingBox": [28, 2234, 96, 2234, 96, 2260, 29, 2259], "text": "Order", "words": [{"boundingBox": [28, 2233, 95, 2233, 95, 2259, 27, 2259], "text": "Order"}]}, {"boundingBox": [376, 2241, 1339, 2238, 1340, 2278, 377, 2280], "text": "Source: https://www.industrydocuments.ucsf.edu/docs/yrvw0217", "words": [{"boundingBox": [380, 2244, 493, 2244, 493, 2278, 379, 2277], "text": "Source:"}, {"boundingBox": [500, 2244, 1335, 2239, 1337, 2278, 499, 2278], "text": "https://www.industrydocuments.ucsf.edu/docs/yrvw0217"}]}]}]}